These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33278337)

  • 1. Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018.
    Rogers H; Adeniyi O; Ramamoorthy A; Bailey S; Pacanowski M
    Clin Transl Sci; 2021 Mar; 14(2):468-475. PubMed ID: 33278337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.
    Black LE; Farrelly JG; Cavagnaro JA; Ahn CH; DeGeorge JJ; Taylor AS; DeFelice AF; Jordan A
    Antisense Res Dev; 1994; 4(4):299-301. PubMed ID: 7734946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
    Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
    JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
    Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
    Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food and Drug Administration Drug Approval Process: A History and Overview.
    Williams CT
    Nurs Clin North Am; 2016 Mar; 51(1):1-11. PubMed ID: 26897420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
    Venkatakrishnan K; Pickard MD; von Moltke LL
    Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical, legal, and ethical issues in expanded access to investigational drugs.
    Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non-orphan drugs approved by the FDA.
    Hsieh J; Sahre M; Yang X; Madabushi R; Ramamoorthy A
    Clin Transl Sci; 2022 Nov; 15(11):2583-2596. PubMed ID: 36165094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
    Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
    Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology aspects of sex-related drug products.
    Tran DC; Apparaju S; Yu C; Lee L; Kim H; Kim MJ
    Clin Pharmacol Ther; 2011 Jan; 89(1):26-8. PubMed ID: 21170068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human radiolabeled mass balance studies supporting the FDA approval of new drugs.
    Ramamoorthy A; Bende G; Chow ECY; Dimova H; Hartman N; Jean D; Pahwa S; Ren Y; Shukla C; Yang Y; Doddapaneni S; Danielsen ZY
    Clin Transl Sci; 2022 Nov; 15(11):2567-2575. PubMed ID: 36066467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
    Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S
    Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
    Qu Y; Henderson KA; Harper TA; Vargas HM
    Clin Pharmacol Ther; 2024 Jul; 116(1):96-105. PubMed ID: 38362953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.